Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 3 study of baricitinib in systemic lupus erythematosus
2017-005028-11Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Status: unknown.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2017-005028-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005028-11.